The SUMMIT trial evaluates Tirzepatide in patients with heart failure with preserved ejection fraction (HFpEF) and obesity, targeting a significant unmet medical need in a growing patient population. Given the increasing prevalence of obesity and heart failure, successful outcomes could position Tirzepatide as a leading treatment option in this therapeutic area, potentially capturing substantial market share. Competitive analysis indicates that while there are existing therapies for HFpEF, Tirzepatide's dual mechanism may offer differentiated benefits. Diligence should focus on the trial's safety profile, particularly in light of the exclusion criteria related to cardiovascular events and diabetes complications, which may impact patient eligibility and market access.